Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

U.S. pharmaceutical company Eli Lilly is expected to disclose the top-line results (key findings from phase 3 clinical trials) of its new drug candidate ‘remternutab,’ being developed as a successor ...

Eli Lilly's potential Alzheimer's disease treatment failed to slow mental decline in two late-stage studies, but combined data from both trials showed promising results in patients with ...

A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the United ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A scientist looks at hypometabolic and hypoperfusion patterns at the single-subject level from a patient suffering ...

The Food and Drug Administration announced Tuesday the approval of a new Alzheimer’s drug from Eli Lilly, which has demonstrated moderately slow cognitive and memory decline in patients with the ...

Investing.com -- Biogen Inc. ’s new at-home Alzheimer’s drug will provide an advantage over Eli Lilly Co. ’s competing ...